Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-08
2011-03-08
Chong, Yong S (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S043000
Reexamination Certificate
active
07902185
ABSTRACT:
Methods for modulating proteasome activity in a subject is provided. Proteasome activity is modulated by administering a therapeutically effective amount of proteasome modulating pharmacological agent to a subject. In a preferred embodiment, the proteasome modulating pharmacological agent is a protease inhibitor. In another aspect, a screening assay for detecting and identifying proteasome modulating pharmacological agents to modulate proteasome activity in a subject is also provided.
REFERENCES:
patent: 5734054 (1998-03-01), Dolle, III et al.
patent: 5843715 (1998-12-01), Bandman et al.
patent: 2003/0232349 (2003-12-01), Delegeane et al.
patent: WO 03/043616 (2003-05-01), None
Kelly et al. (“Proteasome Modulation by Ritonavir Extends the Life of the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis”, Database Accession No. 2003:327040 XP002255235 Abtract, of record).
Hosseini, Hassan et al. “Protection Against Experimental Autoimmune Encephalomyelitis By A Proteasome Modulator” Journal of Neuroimmunotogy, vol. 118, pp. 233-244 (2001).
Qunxing Ding and Keller, Jeffrey N. “Proteasomes And Proteasome Inhibition In The Central Nervous System” Free Radical Biology & Medicine, vol. 31, No. 5, pp. 574-584 (2001).
DeMartino, George N. and Slaughter, Clive A. “The Proteasome, A Novel Protease Regulated by Multiple Mechanisms”, The Journal of Biological Chemistry, vol. 274, No. 32, pp. 22123-22126 (1999).
Andre, Patrice et al. “An Inhibitor of HIV-1 Protease Modulates Proteasome Activity, Antigen Presentation, And T Cell Responses”, Proc. Natl. Acad. Sci, USA, vol. 95, pp. 13120-13124 (1998).
Kelly, N et al. “Proteasome Modulation By Ritonavir Extends The Life of The SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis”, Database Accession No. 2003:327040 XP002255235 Abstract.
Ramesh Tennore M.
Scott Sean
ALS Therapy Development Foundation, Inc.
Chong Yong S
Engellenner Thomas J.
Nutter & McClennen & Fish LLP
LandOfFree
Treatment of neurodegenerative diseases using proteasome... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neurodegenerative diseases using proteasome..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neurodegenerative diseases using proteasome... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2773607